Bharat Parenterals Ltd
Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations[1]
- Market Cap ₹ 770 Cr.
- Current Price ₹ 1,117
- High / Low ₹ 1,870 / 802
- Stock P/E
- Book Value ₹ 480
- Dividend Yield 0.09 %
- ROCE -4.59 %
- ROE -4.78 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 2.13% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.11.6 Cr.
- Company has high debtors of 184 days.
- Promoter holding has decreased over last 3 years: -6.64%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
124 | 111 | 137 | 220 | 228 | 205 | 212 | 218 | 257 | 340 | |
114 | 105 | 124 | 191 | 200 | 179 | 183 | 198 | 234 | 338 | |
Operating Profit | 10 | 7 | 12 | 29 | 28 | 25 | 29 | 20 | 23 | 3 |
OPM % | 8% | 6% | 9% | 13% | 12% | 12% | 14% | 9% | 9% | 1% |
5 | 8 | 7 | 13 | 11 | 9 | 7 | 12 | 9 | 12 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 13 |
Depreciation | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 9 | 35 |
Profit before tax | 9 | 7 | 13 | 35 | 33 | 27 | 28 | 24 | 19 | -34 |
Tax % | 31% | 8% | 29% | 39% | 26% | 25% | 25% | 33% | 44% | 29% |
6 | 7 | 9 | 21 | 24 | 20 | 21 | 16 | 11 | -44 | |
EPS in Rs | 11.26 | 12.03 | 15.92 | 37.09 | 42.13 | 35.59 | 36.45 | 28.47 | 24.95 | -18.33 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 4% | -5% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 17% |
TTM: | 32% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -219% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 37% |
3 Years: | 45% |
1 Year: | -27% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 6% |
3 Years: | 2% |
Last Year: | -5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 |
Reserves | 51 | 58 | 67 | 88 | 112 | 138 | 160 | 177 | 191 | 324 |
19 | 6 | 9 | 5 | 1 | 12 | 18 | 50 | 158 | 180 | |
44 | 40 | 50 | 60 | 68 | 43 | 42 | 118 | 149 | 138 | |
Total Liabilities | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 504 | 649 |
35 | 31 | 34 | 35 | 33 | 45 | 41 | 42 | 210 | 253 | |
CWIP | 0 | 0 | 0 | 1 | 12 | 0 | 26 | 99 | 25 | 30 |
Investments | 0 | 1 | 1 | 1 | 0 | 43 | 11 | 0 | 0 | 5 |
85 | 79 | 98 | 121 | 142 | 111 | 148 | 209 | 269 | 360 | |
Total Assets | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 504 | 649 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
0 | -2 | 6 | 20 | 14 | 24 | -1 | 22 | -5 | -27 | |
0 | -2 | -8 | -9 | -13 | -43 | -7 | -78 | -105 | -137 | |
0 | -8 | 4 | -4 | -3 | 10 | 9 | 61 | 110 | 156 | |
Net Cash Flow | 0 | -11 | 2 | 7 | -1 | -8 | 2 | 4 | 1 | -8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 130 | 143 | 157 | 106 | 127 | 121 | 126 | 188 | 201 | 184 |
Inventory Days | 62 | 70 | 60 | 59 | 71 | 61 | 56 | 100 | 142 | 142 |
Days Payable | 171 | 168 | 110 | 83 | 104 | 71 | 64 | 136 | 138 | 146 |
Cash Conversion Cycle | 21 | 45 | 107 | 82 | 93 | 111 | 118 | 152 | 204 | 180 |
Working Capital Days | 45 | 64 | 92 | 76 | 89 | 112 | 157 | 156 | 201 | 196 |
ROCE % | 11% | 18% | 39% | 31% | 20% | 17% | 11% | 7% | -5% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
1d - BPL reports FY25 strong revenue growth; Innoxel clears USFDA with minor observation; plans global expansion and capex.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14 May - Audio recording of Q4FY25 earnings call made available on May 14, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 May - Publication of newspaper Advertisement for the audited Financial Results for the quarter and year ended on March 31, 2025.
-
THE MANAGEMENT DISCUSSION AND ANAYLSIS FOR THE QUARTER AND YEAR ENDED ON MARCH 31, 2025.
12 May - FY25 results: standalone revenue ₹318.7 Cr (+19.8%), consolidated loss ₹43.7 Cr; US FDA cleared Innoxel facility.
-
Appointment Of Secretarial Auditor, Cost Auditor And Internal Auditor Of The Company.
12 May - Appointment of secretarial, cost, and internal auditors for FY 2025-26 approved by board.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2003
from bse
-
Financial Year 2002
from bse
-
Financial Year 1999
from bse
Concalls
-
May 2025TranscriptPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
Business Overview:[1]
BPL is a Gujarat-based WHO GMP & an ISO 10002: 2014, 9001: 2015 certified pharmaceutical company. It manufactures over 800 products spread over 20+ different categories including General Products, β-Lactum/ Cephalosporin Products, Formulations in the form of Tablets, Capsules, Liquid- orals, Ointments, Creams, Lotions, and most importantly Powdered Injections and small Volume Parenterals both in Ampoules and Vials.